A 2026 scoping review screened 956 systematic reviews/guidelines and 604 original studies on cancer-survivor neuropathic pain, but only 11 pharmacological, 2 psychological, and 3 exercise studies were eligible.1 The practical signal is narrow: duloxetine and some exercise programs have the clearest support, while psychological and interdisciplinary evidence is still too thin for confident treatment ranking. …
A 2026 case series of 5 adults with bodily distress disorder found mean pain scores decreased from 9.0 to 3.8 after accelerated transcranial direct current stimulation, with 4 of 5 patients achieving at least 50% pain reduction.1 The result is a feasibility signal, not proof of efficacy, because every patient knew they were receiving stimulation …
A 2026 targeted metabolomics study of knee osteoarthritis found 33 altered serum metabolites and 10 altered cerebrospinal-fluid metabolites, but the symptom signal split by compartment: serum amino acids, bile acids, and acylcarnitines tracked pain or fatigue, while CSF histamine and 3-hydroxyphenylacetic acid tracked central pain and sleep measures.1 Research Highlights 33 serum metabolites shifted: knee …
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling multisystem illness marked by post-exertional malaise, cognitive dysfunction, pain, sleep disruption, and autonomic symptoms; a 2026 PLOS One qualitative analysis of 505 memorial entries found that bereaved accounts repeatedly placed death inside 4 overlapping contexts: systemic neglect, clinical dismissal, social disconnection, and personal functional collapse.1 Research Highlights …
A 2026 mixed-methods study of 32 chronic non-cancer pain patients found the strongest satisfaction signal when prescribed cannabis-based medicines affected stress, sleep, coping, anxiety, appetite, and daily function — not pain intensity alone.1 Research Highlights 32 patients were interviewed: Pombeiro Stein et al. studied adults from a German pain clinic who had used physician-prescribed cannabis-based …
A 2026 Taiwanese case series reported VAS pain drops in all 3 adults treated with pregabalin for type I complex regional pain syndrome: 9 to 5, 2 to 1, and 6 to 3 after doses of 75-150 mg/day. The signal is clinically interesting because pain relief helped rehabilitation participation, but the evidence remains weak because …
A 2026 case series of 10 adults with refractory postherpetic neuralgia found: 3 of 8 patients responded to a spinal cord stimulation trial, 2 kept meaningful 24-month relief after implantation, and 3 dorsal root entry zone lesioning cases reported 60-90% pain relief at 24 months.1 The data are too small to rank the procedures, but …